Preclinical Detection and Differential Diagnosis of Alzheimer’s Disease Using a Visuospatial Paired Associates Learning Test (CANTAB PAL): Implications for Screening and Clinical Trial Sample Enrichment

Andrew D. Blackwell,Celeste De Jager,Marc Budge,Rachel Swainson,James Semple,Albert Michael,Trevor Robbins,John Hodges,Barbara Sahakian
DOI: https://doi.org/10.1016/j.jalz.2005.06.286
2005-01-01
Abstract:Commencing treatment of Alzheimer's disease (AD) at the time of clinical diagnosis may be sub-optimal or even ineffective because of the advanced stage of neurodegeneration at the time of diagnosis using current criteria. Tests sensitive and specific to preclinical AD are urgently needed for screening, treatment and clinical trial sample enrichment. In a series of studies, the first aim was to identify which neuropsychological tests are most sensitive to the early cognitive sequelae of AD pathology but insensitive to depression in order to facilitate the detection of individuals with preclinical AD. The second aim was to derive a neuropsychological algorithm which could successfully identify individuals in a memory clinic sample who went on to develop AD. The third aim was to apply this neuropsychological algorithm to the early detection of cognitive decline in a community sample of healthy elderly volunteers with no subjective memory complaint. In study 1, tests of memory, attention and executive function were administered to individuals with mild AD, questionable dementia (QD) or major depression and also to healthy elderly volunteers. Incidence of AD was monitored over 32 months. An algorithm for outcome classification was derived using test results at baseline. In study 2, this algorithm was applied to the test results of 155 elderly community-dwelling volunteers reporting good memory and thinking. Cognitive function and incidence of Mild Cognitive Impairment (MCI)/AD were monitored over 4 years. In Study 1a test of visuospatial paired associative learning and memory (CANTAB PAL) most accurately distinguished AD from depressed patients and healthy volunteers. In the QD group, PAL performance, in combination with age and a test of semantic memory, could be used to predict accurately later diagnosis of AD. In study 2, baseline assessment revealed a subgroup of volunteers with deficits in PAL and semantic naming for whom subsequent cognitive decline and relative risk of MCI/AD was significantly higher. This series of studies demonstrated that measures of visuospatial learning and memory are of use in community and clinical dementia screening and for identifying enriched samples for trials of anti-dementia treatments.
What problem does this paper attempt to address?